Intensive Care Medicine

, Volume 42, Issue 11, pp 1818–1819 | Cite as

The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial

  • Matthew S. Duprey
  • Nada Al-Qadheeb
  • Russel Roberts
  • Yoanna Skrobik
  • Greg Schumaker
  • John W. DevlinEmail author


Haloperidol Underlying Risk Factor Rigorous Study Design Haloperidol Dose Subsyndromal Delirium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Swan JT, Fitousis K, Hall JB, Todd SR, Turner KL (2012) Antipsychotic use and diagnosis of delirium in the intensive care unit. Crit Care 16:R84CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Drew BJ, Ackerman MJ, Funk M, American Heart Association Acute Cardiac Care Committee of the Council on Clinical C, Council on Cardiovascular N, American College of Cardiology F et al (2010) Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 55:934–947CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Sharma ND, Rosman HS, Padhi ID, Tisdale JE (1998) Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 81:238–240CrossRefPubMedGoogle Scholar
  4. 4.
    Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H (2001) The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol 41:1310–1318CrossRefPubMedGoogle Scholar
  5. 5.
    Al-Qadheeb NS, Skrobik Y, Schumaker G, Pacheco MN, Roberts RJ, Ruthazer RR, Devlin JW (2016) Preventing ICU subsyndromal delirium conversion to delirium with low-dose IV haloperidol: a double-blind, placebo-controlled pilot study. Crit Care Med 44:583–591CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2016

Authors and Affiliations

  • Matthew S. Duprey
    • 1
  • Nada Al-Qadheeb
    • 2
  • Russel Roberts
    • 3
  • Yoanna Skrobik
    • 4
  • Greg Schumaker
    • 5
  • John W. Devlin
    • 1
    • 5
    Email author
  1. 1.School of PharmacyNortheastern UniversityBostonUSA
  2. 2.Department of Critical CareHafer Albatin Central HospitalRiyadhSaudi Arabia
  3. 3.Department of PharmacyMassachusetts General HospitalBostonUSA
  4. 4.Division of Critical CareMcGill University Health CentreMontrealCanada
  5. 5.Division of Pulmonary, Critical Care and Sleep MedicineTufts Medical CenterBostonUSA

Personalised recommendations